- Early cancer detection technology innovator AnPac Bio-Medical Science Co. Ltd. has been awarded 142 patents with 95 patents pending as part of its bid to revolutionize cancer screening protocols
- AnPac Bio’s proprietary technology screens for a variety of biophysical properties and analyzes the results to establish risk factors for tumor development before tumor cells begin circulating in the bloodstream
- AnPac Bio’s technology can be combined with the more extant tumor cell-detection technology to boost the screening’s effectiveness
- The international company, with operations in the US and China recently named an accomplished bio-medical executive, Dr. Sunil Pandit, as the CEO of its U.S. operations.
The US and China based cancer screening technology innovator
AnPac Bio-Medical Science (NASDAQ: ANPC) is advancing its operations in the United States, announcing Aug. 17 that accomplished bio-medical scientist Dr. Sunil Pandit has been named the CEO of the company’s U.S. operations, AnPac Technology USA Co., Ltd. (or AnPac Bio US).
Dr. Pandit will lead the company’s strategic efforts to increase adoption of AnPac Bio’s early cancer detection technology — the pioneering Cancer Differentiation Analysis (“CDA”) platform that is the company’s…
Read More>>
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at
https://ibn.fm/ANPC
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via
InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with
BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit
https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the
InvestorBrandNetwork.